Literature DB >> 15025540

AMD3100 conjugates as components of targeted nonviral gene delivery systems: synthesis and in vitro transfection efficiency of CXCR4-expressing cells.

Bertrand Le Bon1, Nathalie Van Craynest, Jean-Michel Daoudi, Christophe Di Giorgio, Abraham J Domb, Pierre Vierling.   

Abstract

We describe the synthesis of a series of AMD3100-lipid and AMD3100-polycationic conjugates which were used as components of targeted lipoplexes (in conjunction with (poly)cationic lipids) and polyplexes, respectively, for mediating specific gene transfer into cells expressing CXCR4 which displays a high affinity for AMD3100. Transfection studies were investigated with suspension CXCR4(+) human lymphoma Jurkat cells and with adherent CXCR4(-) human glioblastoma T98G and human lung carcinoma A549 cells lines in order to demonstrate a receptor-mediated endocytosis pathway and to minimize nonspecific transfection pathways. Altogether, our results show that polyplexes formulated with AMD-labeled polymers constitute, under certain conditions, specific gene transfer systems into suspension CXCR4(+) Jurkat cells. This is more particularly the case when the nonspecific transfection pathways are minimized (i.e. for N/P <or= 2.5 AMD-labeled polyplexes) and in the presence of phorbol myristate acetate which triggers CXCR4 receptor endocytosis of the AMD-labeled polyplexes to a larger extent than that of their respective nonlabeled ones. Although encouraging, the transfection specificities and efficiencies obtained with these compounds should however be improved. This study also illustrates the difficulties to demonstrate and to obtain a specific and efficient gene transfer system with cationized ligand-labeled DNA particles which also provide receptor-independent nonspecific gene transfer to cells, and more particularly to adherent cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15025540     DOI: 10.1021/bc034220o

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  5 in total

1.  CXCR4-Targeted Nanocarriers for Triple Negative Breast Cancers.

Authors:  Asish C Misra; Kathryn E Luker; Hakan Durmaz; Gary D Luker; Joerg Lahann
Journal:  Biomacromolecules       Date:  2015-07-22       Impact factor: 6.988

2.  CXCR-4 Targeted, Short Wave Infrared (SWIR) Emitting Nanoprobes for Enhanced Deep Tissue Imaging and Micrometastatic Cancer Lesion Detection.

Authors:  Margot Zevon; Vidya Ganapathy; Harini Kantamneni; Marco Mingozzi; Paul Kim; Derek Adler; Yang Sheng; Mei Chee Tan; Mark Pierce; Richard E Riman; Charles M Roth; Prabhas V Moghe
Journal:  Small       Date:  2015-10-30       Impact factor: 13.281

3.  Potential of CXCR4/CXCL12 Chemokine Axis in Cancer Drug Delivery.

Authors:  Yan Wang; Ying Xie; David Oupický
Journal:  Curr Pharmacol Rep       Date:  2016-01-04

4.  Modified chitosan for effective renal delivery of siRNA to treat acute kidney injury.

Authors:  Weimin Tang; Sudipta Panja; Chinmay M Jogdeo; Siyuan Tang; Ling Ding; Ao Yu; Kirk W Foster; Del L Dsouza; Yashpal S Chhonker; Heather Jensen-Smith; Hee-Seong Jang; Erika I Boesen; Daryl J Murry; Babu Padanilam; David Oupický
Journal:  Biomaterials       Date:  2022-05-02       Impact factor: 15.304

5.  Synergistic Anti-Angiogenic Effects Using Peptide-Based Combinatorial Delivery of siRNAs Targeting VEGFA, VEGFR1, and Endoglin Genes.

Authors:  Anna A Egorova; Sofia V Shtykalova; Marianna A Maretina; Dmitry I Sokolov; Sergei A Selkov; Vladislav S Baranov; Anton V Kiselev
Journal:  Pharmaceutics       Date:  2019-06-06       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.